ZW-251

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameZW-251
Drug Alias NameZW-251
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Cleavable peptide linker
Mechanisms of ActionAnti-Glypican-3DNA topoisomerase I inhibitors
TargetsGlypican-3DNA topoisomerase I
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, HepatocellularNeoplasms, Germ Cell and Embryonal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPortugal +[6] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesZymeworks Inc
China Registration ClassN/A

Develop Information

Active CompaniesZymeworks IncZymeworks BC Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungCarcinoma, HepatocellularNeoplasms, Germ Cell and Embryonal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A